Zobrazeno 1 - 10
of 300
pro vyhledávání: '"Kurt A. Schalper"'
Autor:
Sneha Burela, Mengni He, Ioannis P. Trontzas, Niki Gavrielatou, Kurt A. Schalper, Solomon Langermann, Dallas B. Flies, David L. Rimm, Thazin N. Aung
Publikováno v:
Discover Oncology, Vol 15, Iss 1, Pp 1-11 (2024)
Abstract Basal Cell Adhesion Molecule (BCAM), a receptor for laminin subunit α5, plays a crucial role in the pathogenesis of various malignancies. Notably, evidence of hypermethylation at multiple immune checkpoints in patients with low BCAM express
Externí odkaz:
https://doaj.org/article/e06f9eb926d740f08bba636b5ace8940
Autor:
Arta M. Monjazeb, Megan E. Daly, Guillaume Luxardi, Emanual Maverakis, Alexander A. Merleev, Alina I. Marusina, Alexander Borowsky, Amin Mirhadi, Stephen L. Shiao, Laurel Beckett, Shuai Chen, David Eastham, Tianhong Li, Logan V. Vick, Heather M. McGee, Frances Lara, Leslie Garcia, Leigh Anne Morris, Robert J. Canter, Jonathan W. Riess, Kurt A. Schalper, William J. Murphy, Karen Kelly
Publikováno v:
Nature Communications, Vol 14, Iss 1, Pp 1-14 (2023)
Abstract Stereotactic ablative radiotherapy (SABR) is a standard-of-care for medically-inoperable-early-stage non-small cell lung cancer (NSCLC). One third of patients progress and chemotherapy is rarely used in this population. We questioned if addi
Externí odkaz:
https://doaj.org/article/28952647439e48d680160b1ba89a37c4
Autor:
Sandra Martinez-Morilla, Myrto Moutafi, Aileen I. Fernandez, Shlomit Jessel, Prajan Divakar, Pok Fai Wong, Rolando Garcia-Milian, Kurt A. Schalper, Harriet M. Kluger, David L. Rimm
Publikováno v:
OncoImmunology, Vol 12, Iss 1 (2023)
ABSTRACTAlthough immune checkpoint inhibitor (ICI) therapy has dramatically improved outcome for metastatic melanoma patients, many patients do not benefit. Since adverse events may be severe, biomarkers for resistance would be valuable, especially i
Externí odkaz:
https://doaj.org/article/61850931c801456bb2e5a14b003e557a
Autor:
Paolo A. Ascierto, Carlo Bifulco, Luigi Buonaguro, Leisha A. Emens, Robert L. Ferris, Bernard A. Fox, Greg M. Delgoffe, Jérôme Galon, Cesare Gridelli, Marco Merlano, Paul Nathan, Kunle Odunsi, Hideho Okada, Chrystal M. Paulos, Sandro Pignata, Kurt A. Schalper, Stefani Spranger, Giampaolo Tortora, Hassane Zarour, Lisa H. Butterfield, Igor Puzanov
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 7, Iss 1, Pp 1-20 (2019)
Abstract Immunotherapy is now widely established as a potent and effective treatment option across several types of cancer. However, there is increasing recognition that not all patients respond to immunotherapy, focusing attention on the immune cont
Externí odkaz:
https://doaj.org/article/521b648e5d4848b4b2defdca6c669e8b
Autor:
Andrew B. Nixon, Kurt A. Schalper, Ira Jacobs, Shobha Potluri, I-Ming Wang, Catherine Fleener
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 7, Iss 1, Pp 1-14 (2019)
Abstract The immunologic landscape of the host and tumor play key roles in determining how patients will benefit from immunotherapy, and a better understanding of these factors could help inform how well a tumor responds to treatment. Recent advances
Externí odkaz:
https://doaj.org/article/ab04ae0cd4854d0181710f053db51ee0
Autor:
Daniel Carvajal-Hausdorf, Mehmet Altan, Vamsidhar Velcheti, Scott N. Gettinger, Roy S. Herbst, David L. Rimm, Kurt A. Schalper
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 7, Iss 1, Pp 1-9 (2019)
Abstract Background Small cell lung cancer (SCLC) accounts for 10–15% of all lung malignancies and its prognosis is dismal. Although early studies have shown promising clinical activity of immune checkpoint blockers, the immune composition and expr
Externí odkaz:
https://doaj.org/article/95ad26b6988545f3b24fc5c049322f04
Autor:
Vasiliki Pelekanou, Franz Villarroel-Espindola, Kurt A. Schalper, Lajos Pusztai, David L. Rimm
Publikováno v:
Breast Cancer Research, Vol 20, Iss 1, Pp 1-10 (2018)
Abstract Background The role of tumor-associated macrophages (TAMs) in the cancer immune landscape and their potential as treatment targets or modulators of response to treatment are gaining increasing interest. TAMs display high molecular and functi
Externí odkaz:
https://doaj.org/article/398c1826a9c243298132c937a360eb36
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 6, Iss 1, Pp 1-13 (2018)
Abstract Background Immunotherapy is at the forefront of modern oncologic care. Various novel therapies have targeted all three layers of tumor biology: tumor, niche, and immune system with a range of promising results. One emerging class in both pri
Externí odkaz:
https://doaj.org/article/beb5bcf9f277480294b0437be21c9d79
Autor:
Daniel E. Carvajal-Hausdorf, Nikita Mani, Vamsidhar Velcheti, Kurt A. Schalper, David L. Rimm
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 5, Iss 1, Pp 1-9 (2017)
Abstract Background Immunostimulatory therapies targeting immune-suppressive pathways produce durable responses in advanced solid tumors. Indoleamine 2,3-dioxygenase (IDO) is the rate-limiting oxidoreductase that catalyzes the degradation of tryptoph
Externí odkaz:
https://doaj.org/article/5da7235e84ce4562856d83faaf9eb4f2
Autor:
Francisco Barrera, Lorena Azocar, Héctor Molina, Kurt A. Schalper, Marcia Ocares, Jessica Liberona, Luis Villarroel, Fernando Pimentel, Rosa M. Pérez-Ayuso, Flavio Nervi, Albert K. Groen, Juan F. Miquel
Publikováno v:
Annals of Hepatology, Vol 14, Iss 5, Pp 710-721 (2015)
Background and rationale for the study. FGF19/15 is a gut-derived hormone presumably governing bile acid (BA) synthesis and gallbladder (GB) refilling. FGF19 mRNA is present in human GB cholangiocytes (hGBECs); however, the physiological significance
Externí odkaz:
https://doaj.org/article/4f36d2ee70f3407485f572df30b96ee5